Stem Cell Companies Innovating For The Future

Many medical companies throughout the world are pinning their hopes for miracle cures on stem cell therapies. Because of the ability of stem cells to differentiate into all cells within the body, they are central to the field of regenerative medicine, which seeks to restore or establish normal healthy functions in patients with serious disorders by regenerating human cells, tissues or organs.I would not reference embryonic stem  cells – we use adult stem cells and embryonic cells are a whole other animal with certain aged baggage.

Two companies in particular that have caught our attention are BioRestorative Therapies, Inc. (OTCQB: BRTX), and Sangamo Therapeutics, Inc. (NASDAQ: SGMO)

A month ago, Defined Health (a pharma and targeted scientific consulting firm) conducted an independent review of BRTX-100, which is BioRestorative Therapies, Inc. lead cell therapy candidate designed to treat chronic Lumbar Disc Disease (cLDD). As the report concluded, the Key Opinion Leaders (KOLs) reacted positively to the value proposition of BRTX-100 and scientists are optimistic that the clinical data presented to date is likely to be mirrored in future clinical investigations. If BRTX-100 were to be granted FDA approval, KOLs anticipate that it would be integrated into the standard of care for eligible cLDD patients.

These stem cell companies are innovating for the future: BioRestorative Therapies, Inc. (OTCQB: BRTX), Sangamo Therapeutics, Inc. (NASDAQ: SGMO)

BioRestorative Therapies, Inc. (OTCQB: BRTX)

Market Cap: $11.17M, current share price: $1.70

BioRestorative Therapies, Inc. develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Today, BioRestorative is actively developing programs that aim to dramatically increase quality of care for both (i) chronic back pain caused by disc degeneration, as well as (ii) metabolic disorders including obesity and diabetes.

BRTX-100 is a novel product to treat damaged, degenerating discs, and is anticipated to be safer, cheaper, and more effective upon a single treatment. Specifically, BRTX-100 is an autologous stem cell product that uses your own stem cells that are harvested, cultured, and then injected directly into the affected disc to start the repair process.

To target obesity and metabolic disorders, they developed their ThermoStem® program that uses brown adipose-derived (“brown fat”) stem cells to generate new brown fat tissue. BioRestorative Therapies was one of the first companies to identify and publish data about this novel stem cell population. This population of fat is known to burn, rather than store, energy.  Elevated levels of brown fat have been demonstrated to increase metabolism and facilitate weight loss. Initial preclinical research indicates that increased amounts of activated brown fat in the body may be responsible for additional caloric burning, as well as reduced glucose and lipid levels.  

Sangamo Therapeutics, Inc. (NASDAQ: SGMO)

Market Cap: $1.59B, current share price: $15.70

Sangamo Therapeutics, Inc. focuses on translating ground-breaking science into genomic therapies that transform patients’ lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company’s zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off. Its therapeutic products include SB-728-T, a ZFN-mediated autologous T-cell product for human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS), which is in Phase II and Phase I clinical trials; and SB-728-HSPC that is in Phase I/II clinical trials for HIV/AIDS. 

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two.  ACR Communication, LLC has been compensated one thousand dollars cash for this article and one thousand dollars total by Regal Consulting. LLC, for news commentary articles for BRTX.  BRTX and Regal Consulting, LLC were given an opportunity to edit information included in this article.  This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information.  ACR Communication, LLC, will not buy or sell any shares in stocks contained within this article for forty eight hours after this article’s distribution.

For Full Legal Disclaimer Click Here.

Contact Information:

Company Name: Microcap Speculators

Contact Person: Media Manager


Phone: 1-702-720-6310

Country: United States